ATE231549T1 - Verfahren zur konservierung von infektiösen rekombinierenden viren, virale wässrige suspension und ihre medizinische verwendung - Google Patents

Verfahren zur konservierung von infektiösen rekombinierenden viren, virale wässrige suspension und ihre medizinische verwendung

Info

Publication number
ATE231549T1
ATE231549T1 AT97933740T AT97933740T ATE231549T1 AT E231549 T1 ATE231549 T1 AT E231549T1 AT 97933740 T AT97933740 T AT 97933740T AT 97933740 T AT97933740 T AT 97933740T AT E231549 T1 ATE231549 T1 AT E231549T1
Authority
AT
Austria
Prior art keywords
viruses
viral
recombining
aqueous suspension
medical use
Prior art date
Application number
AT97933740T
Other languages
German (de)
English (en)
Inventor
Claude Sene
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Application granted granted Critical
Publication of ATE231549T1 publication Critical patent/ATE231549T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04—Preserving or maintaining viable microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AT97933740T 1996-07-16 1997-07-15 Verfahren zur konservierung von infektiösen rekombinierenden viren, virale wässrige suspension und ihre medizinische verwendung ATE231549T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9608851A FR2751343B1 (fr) 1996-07-16 1996-07-16 Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
PCT/FR1997/001308 WO1998002522A1 (fr) 1996-07-16 1997-07-15 Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament

Publications (1)

Publication Number Publication Date
ATE231549T1 true ATE231549T1 (de) 2003-02-15

Family

ID=9494078

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97933740T ATE231549T1 (de) 1996-07-16 1997-07-15 Verfahren zur konservierung von infektiösen rekombinierenden viren, virale wässrige suspension und ihre medizinische verwendung

Country Status (11)

Country Link
US (2) US6451256B1 (enFirst)
EP (1) EP0853660B1 (enFirst)
JP (1) JP3681401B2 (enFirst)
AT (1) ATE231549T1 (enFirst)
AU (1) AU711409B2 (enFirst)
CA (1) CA2232604C (enFirst)
DE (1) DE69718612T2 (enFirst)
DK (1) DK0853660T3 (enFirst)
ES (1) ES2187798T3 (enFirst)
FR (1) FR2751343B1 (enFirst)
WO (1) WO1998002522A1 (enFirst)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080261289A1 (en) * 1996-12-13 2008-10-23 Schering-Plough Corporation Compositions comprising viruses and methods for concentrating virus preparations
US6544769B1 (en) * 1996-12-13 2003-04-08 Schering Corporation Compostions comprising viruses and methods for concentrating virus preparations
US6759050B1 (en) 1998-12-03 2004-07-06 Avigen, Inc. Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
CA2353417C (en) * 1998-12-03 2008-04-22 Genzyme Corporation Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
US6225289B1 (en) * 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
FR2791999B1 (fr) * 1999-04-09 2001-09-07 Aventis Pharma Sa Composition destinee a la conservation d'adenovirus recombinants infectieux
CN1347450A (zh) * 1999-04-09 2002-05-01 阿文蒂斯药物股份有限公司 用于保存感染性重组腺病毒的组合物
CA2799545A1 (en) 2000-03-07 2001-09-13 Merck Sharp & Dohme Corp. Adenovirus formulations
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
EP1284287A4 (en) * 2000-05-10 2004-10-13 Mitsubishi Pharma Corp METHOD FOR PRODUCING A VIRUS VECTOR
JP4550421B2 (ja) 2001-12-12 2010-09-22 メイン・ファ−マ・インタ−ナショナル・プロプライエタリ−・リミテッド ウイルスの保存のための組成物
BR0306925A (pt) * 2002-01-18 2004-11-09 Schering Ag Formulações estabilizadas de adenovìrus
KR100507794B1 (ko) * 2003-02-11 2005-08-17 한미약품 주식회사 고농도 레트로 바이러스 현탁액 제조 방법
EP1692279A4 (en) * 2003-11-19 2006-12-27 Merck & Co Inc VIRUS PREPARATIONS CONTAINING A CONSERVATIVE
CN1922308A (zh) * 2004-02-23 2007-02-28 克鲁塞尔荷兰公司 病毒纯化方法
GB0502661D0 (en) * 2005-02-09 2005-03-16 Stabilitech Ltd A desiccated product
CA2602944C (en) * 2005-04-11 2015-08-11 Crucell Holland B.V. Virus purification using ultrafiltration
CN1961961B (zh) * 2005-11-11 2010-05-26 深圳市源兴生物医药科技有限公司 一种药物制剂及其制备方法
WO2010060719A1 (en) 2008-11-03 2010-06-03 Crucell Holland B.V. Method for the production of adenoviral vectors
EP2536829B1 (en) 2010-02-15 2016-04-06 Crucell Holland B.V. Method for the production of Ad26 adenoviral vectors
EP2618838A1 (en) 2010-09-20 2013-07-31 Crucell Holland B.V. Therapeutic vaccination against active tuberculosis
US9168292B2 (en) 2010-09-27 2015-10-27 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
CA2819246C (en) 2010-12-02 2023-04-25 Oncolytics Biotech Inc. Liquid viral formulations
US9044498B2 (en) 2010-12-02 2015-06-02 Oncolytics Biotech Inc. Lyophilized viral formulations
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
CA2864956C (en) 2012-03-12 2021-11-09 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
AP2014007993A0 (en) 2012-03-22 2014-10-31 Crucell Holland Bv Vaccine against RSV
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
CA2878800A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterial antigen vaccine
CN110590916A (zh) 2013-04-25 2019-12-20 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
KR102313153B1 (ko) 2013-06-17 2021-10-15 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 가용성 예비융합 ｒｓｖ ｆ 폴리펩타이드
RU2695462C2 (ru) 2014-01-09 2019-07-23 Трансген Са Гибридизация гетероолигомерных микобактериальных антигенов
US9721484B2 (en) 2014-06-23 2017-08-01 Humanetics Innovative Solutions, Inc. Shoulder kit assembly for crash test dummy
DK3552615T3 (da) 2014-07-16 2022-02-14 Transgene Onkolytisk virus til ekspression af immun-checkpoint-modulatorer
US10008130B2 (en) 2014-09-17 2018-06-26 Humanetics Innovative Solutions, Inc. Omni-directional shoulder assembly for crash test dummy
EP3256156B1 (en) 2015-02-13 2025-02-12 Transgene Immunotherapeutic vaccine and antibody combination therapy
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
SI3283634T1 (sl) 2015-04-14 2019-08-30 Janssen Vaccines & Prevention B.V. Rekombinantni adenovirus, ki izraža dva transgena z dvosmernim promotorjem
JP7189014B2 (ja) 2015-07-07 2022-12-13 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｒｓｖに対するワクチン
US10457708B2 (en) 2015-07-07 2019-10-29 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
BR112018070323A2 (pt) 2016-04-05 2019-01-29 Janssen Vaccines & Prevention Bv vacina contra rsv
KR20220041966A (ko) 2016-04-05 2022-04-01 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 용해성 융합-전 rsv f 단백질
WO2017194655A1 (en) 2016-05-12 2017-11-16 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
IL264119B2 (en) 2016-05-30 2023-04-01 Janssen Vaccines Prevention B V f proteins of rsv are stabilized before fusion
EP3472327B1 (en) 2016-06-20 2020-08-19 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
EP3484506A1 (en) 2016-07-14 2019-05-22 Janssen Vaccines & Prevention B.V. Hpv vaccines
WO2018049261A1 (en) 2016-09-09 2018-03-15 Icellhealth Consulting Llc Oncolytic virus expressing immune checkpoint modulators
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
US20190330655A1 (en) 2016-12-28 2019-10-31 Transgene Sa Oncolytic viruses and therapeutic molecules
CN110268061B (zh) 2017-02-09 2024-07-16 扬森疫苗与预防公司 用于表达异源基因的有效的短启动子
AU2018267971A1 (en) 2017-05-17 2019-11-07 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against RSV infection
WO2018210871A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
SG11202001458SA (en) 2017-09-15 2020-03-30 Janssen Vaccines & Prevention Bv Method for the safe induction of immunity against rsv
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
US12263197B2 (en) 2018-10-30 2025-04-01 The University Of Tokyo Oncolytic virus for cancer therapy
JOP20210106A1 (ar) 2018-11-13 2023-01-30 Janssen Vaccines And Prevention B V بروتينات rsv f سابقة الاندماج مستقرة
CN121360236A (zh) 2019-03-01 2026-01-20 阿奇洛伊斯生物制药公司 在抗原特异性免疫细胞中调节cd160功能的方法及其用途
BR112022014808A2 (pt) 2020-01-31 2022-09-20 Beth Israel Deaconess Medical Ct Inc Composições e métodos para vacinas para prevenir e tratar infecção pelo coronavírus-sars-cov-2
BR112022018615A2 (pt) 2020-03-19 2022-12-20 Trizell Ltd Sistema de armazenamento de vírus sensível à temperatura
EP4178605A1 (en) 2020-07-13 2023-05-17 Transgene Treatment of immune depression
EP4303233A4 (en) 2021-02-01 2025-05-07 St Phi Therapeutics Co., Ltd. Targeted protein degradation system and use thereof
AU2022221983A1 (en) 2021-02-19 2023-08-17 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv fb antigens
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023025899A2 (en) 2021-08-26 2023-03-02 Transgene Delivery system for targeting genes of the interferon pathway
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
US20260015405A1 (en) 2022-07-01 2026-01-15 Transgene Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
CN120380015A (zh) 2022-08-18 2025-07-25 特兰斯吉恩公司 嵌合痘病毒
WO2026041811A1 (en) 2024-08-23 2026-02-26 Transgene Recombinant poxvirus and method for regulating the expression of toxic conditional gene products of said recombinant poxvirus in a producing cell

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2668064B1 (fr) * 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
US5658779A (en) * 1992-03-20 1997-08-19 Ligochem, Inc. Method of adsorbing viruses from fluid compositions
CA2158935A1 (en) * 1993-10-12 1995-04-20 Chiron Viagene, Inc. Methods for preserving recombinant viruses
FR2711523B1 (fr) * 1993-10-26 1996-02-16 Transgene Sa Procédé de préparation d'un aérosol viral.
US5545555A (en) * 1994-07-25 1996-08-13 Microtest, Inc. Microbial transport media
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5616487A (en) * 1994-09-15 1997-04-01 Aastrom Biosciences, Inc. Stabilized retrovirus compositions
US5932223A (en) * 1996-09-26 1999-08-03 Merck & Co., Inc. Rotavirus vaccine formulations

Also Published As

Publication number Publication date
EP0853660A1 (fr) 1998-07-22
US20030082206A1 (en) 2003-05-01
CA2232604A1 (fr) 1998-01-22
EP0853660B1 (fr) 2003-01-22
WO1998002522A1 (fr) 1998-01-22
DE69718612T2 (de) 2003-11-06
CA2232604C (fr) 2005-06-28
US6451256B1 (en) 2002-09-17
JP3681401B2 (ja) 2005-08-10
DK0853660T3 (da) 2003-05-05
AU3698697A (en) 1998-02-09
DE69718612D1 (de) 2003-02-27
FR2751343B1 (fr) 1998-12-18
AU711409B2 (en) 1999-10-14
FR2751343A1 (fr) 1998-01-23
JP2000500026A (ja) 2000-01-11
ES2187798T3 (es) 2003-06-16

Similar Documents

Publication Publication Date Title
ATE231549T1 (de) Verfahren zur konservierung von infektiösen rekombinierenden viren, virale wässrige suspension und ihre medizinische verwendung
EA200400376A1 (ru) Пептиды, полученные из казеина, и их использование в терапии
DE69841982D1 (de) Zusammensetzungen zum einsatz in einer gentherapie zur behandlung von hämophilie
ATE451835T1 (de) Therapeutische verfahren und zusammensetzungen unter verwendung von viren der rekombinanten familie der paramyxoviridae
EP0431129A4 (en) Methods for the inactivation of viruses in viral-contaminated pharmaceutical compositions
ATE217144T1 (de) Verfahren und zusammensetzungen zur selektiven modifikation von nukleinsaeuren
ATE209686T1 (de) Adenovirale vektoren tierischen ursprungs und ihre verwendung bei der gentherapie
DE60239394D1 (de) Onkolytische virustherapie
FI961536A0 (fi) Menetelmä virusten inaktivoimiseksi polyalkeeniglykolin läsnäollessa samoin kuin siten saatu farmaseuttinen valmiste
DE60009146D1 (de) Pharmazeutische zubereitungen zur behandlung von dns viraler infektionen, welche ein schleifendiureticum und ein herzglykosid enthalten
ATE189394T1 (de) Methode zur behandlung von viralen infektionen
EA199800526A1 (ru) Производные бензимидазола и их применение для лечения вирусных инфекций
KR20040078639A (ko) 카세인 유도 펩타이드 및 이들의 치료 용도
ATE298582T1 (de) Verfahren zur inaktivierung von viren und lyophilisierung von blutproteinen
DE69534633D1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
DK82892D0 (da) Anvendelse af braadgifte fra bier og hvepse til fremstilling af laegemidler til behandling af infektioner
PT85093A (fr) Vecteur viral et procede de preparation de adn recombinant codant pour la proteine f du virus agent causal du s.i.d.a.
ATE292177T1 (de) Gentherapy von lungenkrankheiten
ATE255417T1 (de) Verwendung von bradykinin-antagonisten zur behandlung von viruserkrankungen
DE69231465D1 (de) Methode und zusammensetzung zur behandlung von herpes ähnlichen krankheiten
DE60040910D1 (de) Inaktivierte zytokine zur immunisierung
DE69006187D1 (de) Verwendung von Chinolyl- und Isochinolyloxazol-2-onen zur Herstellung eines Arzneimittels zur Verhinderung der Ansteckungsfähigkeit von mit Glykoproteinen umhüllten Viren.
RU98117264A (ru) Способ инактивации вируса иммунодефицита человека и других вирусов в плазме крови человека с сохранением функциональной активности белков плазмы крови

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0853660

Country of ref document: EP